Gunsan Era (1953~1967)

Dai Han Drug Chemical Industry settled at Gunsan in 1952 began a new start in 14 Yeonghwa-dong, Gunsan-si. We began the second advancement for the will established in Myeongdong, Seoul 8 years ago.

Starting with the plasma injectable solution, the company began reestablishing the production basis for ampule injectable solutions. When the basis for ampule injection solution was secured, a plan for manufacturing the infusion solution began its actualization, The most important part for manufacturing was the procurement of glass bottle and raw material.

The company solved the production of a infusion container through the establishment of 'Korea Special Glassblower Industry' which was the first glass bottle for infusion in 1953. The company prepared the basis for the comfortably supply of infusion through the stable supply of glass bottles and raw materials by the development of a infusion, 'Inveton (invert sugar)' in 1959.
Later, we grew day-by-day through active production. When the administrative system and the economy began settling again around Seoul in the 1960s, Dai Han Drug Chemical Industry also began the preparation of transferring to set the business base in Seoul.
The company installed the marketing head office in Seoul and established a new marketing organization, and prepared a company site at Suyu-ri. However, the death of the founder Insil Lee delayed the transfer to Seoul. By the year 1968, the company was finally able to move to Banghwa-dong, Seoul.

Banghwa-dong Era (1968~1982)

In August 1968, Dai Han Drug Chemical Industry left Gunsan Era behind and built a new plant at Banghwa-dong to open the second era in Seoul.
The company changed its company name to 'Dai Han Pharm. Co., Ltd.' and appointed a new CEO to reform the atmosphere. The company then put the best effort to diversify the manufacturing technology and products for the next stage.

In 1970, when the chairman Yoonwoo Lee who is the eldest son of Mr. Insil Lee the founder of the company began participating in the management, he contributed to the stability and development of the company by raising the competitiveness of the company through a bold investment and a technological development.

In 1977, when the company introduced the Bottle Pack System of Germany to manufacture infusion in a plastic container for the first time in Korea and to focus on the development of a special infusion with various functions like a infusion for liver disease including the electrolyte infusion such as Darrow Solution and Hartmann's Solution, the company began to form an appearance of a comprehensive company for infusion. Receiving a credit for the continuously accumulated technology and product reliability, the company was designated for the national emergency industrial mobilization company and gradually began increasing the market share rate.

In 1978, the company again changed its company name from Dai Han Drug Chemical Industry to Dai Han Pharm. Co., Ltd. which has been used until today with unchanging affection and pride.

Ansan Era (1982~2004)

In March, 1982, the company completed a high-notch plant that had introduced automated machines to the entire facilities for production and quality management at Banwol Industrial Complex in Wonsi-dong, Ansan-si in Gyeonggi-do and finished the Banghwa-dong Era for 15 years to open a new era.
Through the introduction of automated machines over entire production facilities, the company was able to establish an automated system for infusion. The decisive introduction of the facility at that time became a driving force to keep the solid position in the market for infusion.

In 1985, the main office was built in Yangpyung-dong. The CEO, staff, a management office, and a marketing team in charge of Seoul and the capital area of Gyeonggi-do moved in to form an appearance of a worthy of name main office.

The era of responsible management began in a full-scale when Yoonwoo Lee who entered the management front line as a young age in the 20s since 1970 was inaugurated as the fifth CEO on April 8, 1992. In addition, under the judgment that the future of pharmaceutics depended on the technological development, the company initiated an exclusive team for composite research in early 1980s and established a central research center for the major areas of a API synthesis study, a production technology study and a product manufacturing study in 1987.

Dai Han Pharm. Co., Ltd. received the multilateral domestic recognition for the technology with the certificate of KGMP and the selection of INNO-BIZ, and suggested a new vision so called an overseas advancement and developed two directions of a collection of technology information and a pioneering of markets. Beginning with China, the company proclaimed the full-scale advancement to the overseas stage. In addition, the company participated in the South-North Korea Exchange and North Korea Project and gave an advice for the production facility for infusion and implemented social responsibility.

Ansan Era-Takeoff Stage (2004~Present)

On October 14, 2005, during the 60th anniversary of launching Dai Han Pharm. Co., Ltd., the company completed the latest plant for infusion solution at Ansan, which introduced cGMP concept being grafted with the accumulated experience and the international trend of manufacturing facility.
Based on this, the company provided a blueprint for the world pharmaceutical company with three key words of the excellent quality conforming to the international level, the development of new products, and the discovery of new overseas business models.

In 2009, as the chairman Yoonwoo Lee was elected for the president of the Korea Pharmaceutical Traders Association, the overall expectation for the overseas business rose. The third generation of the founder, the executive director Lee Seung Young started leading the overseas business team for uneasy challenge so called 'Pioneering to Global Markets'. After a long run in unyielding momentum, the company accomplished the award of export tower in 2009. In addition, a continuous and bold investment on the development of new products became a cornerstone for future value.
On 2013 Public Health Day, the chairman Yoonwoo Lee of Dai Han Pharm. Co., Ltd. received a national medal for the merit of contribution to the national health. Under the flagship of a value so called 'National Public Health', the will continued to keep one unchanging path to come to a light.
The new plant of cGMP concept completed during the 60th anniversary of foundation became insufficient due to the rapid growth of the company, the chairman decided to expand and rebuild the plant. On October 14, 2015, during the 70th anniversary of foundation, a new plant was completed and remains up to the present.

Dai Han Pharm. Co., Ltd. has been leading the technology and market for infusion solution. Beyond a current comprehensive drug company to supply several hundreds of treatment drugs, the company will put an effort to be reborn as a public health related comprehensive maker up to manufacturing facilities, medical equipments, and health functional products including drugs.